Mazindol

Jump to: navigation, search
Mazindol
Mazindol.png
Clinical data
Routes of
administration
Oral
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability93%
MetabolismHepatic
Elimination half-life10-13 hours
ExcretionRenal
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC16H13ClN2O
Molar mass284.74 g/mol

WikiDoc Resources for Mazindol

Articles

Most recent articles on Mazindol

Most cited articles on Mazindol

Review articles on Mazindol

Articles on Mazindol in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Mazindol

Images of Mazindol

Photos of Mazindol

Podcasts & MP3s on Mazindol

Videos on Mazindol

Evidence Based Medicine

Cochrane Collaboration on Mazindol

Bandolier on Mazindol

TRIP on Mazindol

Clinical Trials

Ongoing Trials on Mazindol at Clinical Trials.gov

Trial results on Mazindol

Clinical Trials on Mazindol at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Mazindol

NICE Guidance on Mazindol

NHS PRODIGY Guidance

FDA on Mazindol

CDC on Mazindol

Books

Books on Mazindol

News

Mazindol in the news

Be alerted to news on Mazindol

News trends on Mazindol

Commentary

Blogs on Mazindol

Definitions

Definitions of Mazindol

Patient Resources / Community

Patient resources on Mazindol

Discussion groups on Mazindol

Patient Handouts on Mazindol

Directions to Hospitals Treating Mazindol

Risk calculators and risk factors for Mazindol

Healthcare Provider Resources

Symptoms of Mazindol

Causes & Risk Factors for Mazindol

Diagnostic studies for Mazindol

Treatment of Mazindol

Continuing Medical Education (CME)

CME Programs on Mazindol

International

Mazindol en Espanol

Mazindol en Francais

Business

Mazindol in the Marketplace

Patents on Mazindol

Experimental / Informatics

List of terms related to Mazindol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Mazindol is a central nervous system stimulant. It is a tricyclic compound (not to be confused with tricyclic antidepressants).

Indications

Mazindol is used in short-term (i.e., a few weeks) treatment of exogenous obesity, in combination with a regimen of weight reduction based on caloric restriction, exercise, and behavior modification in patients with a body mass index of 30 kg of body weight per height in meters squared (kg/m2), or in patients with a body mass index of 27 kg/m2 in the presence of risk factors such as hypertension, diabetes, or hyperlipidemia.

Pharmacology

Mazindol is a sympathomimetic amine, which is similar to amphetamine. It stimulates the central nervous system, which increases heart rate and blood pressure, and decreases appetite. Sympathomimetic anoretics (appetite suppressants) are used in the short-term treatment of obesity. Their appetite-reducing effect tends to decrease after a few weeks of treatment. Because of this, these medicines are useful only during the first few weeks of a weight-loss program.

Mechanism of Action

Although the mechanism of action of the sympathomimetics in the treatment of obesity is not fully known, these medications have pharmacological effects similar to those of amphetamines. Like other sympathomimetic appetite suppressants such as phentermine, mazindol is thought to act as a reuptake inhibitor of norepinephrine.

Frame

Overdose

Symptoms of a mazindol overdose include: restlessness, tremor, rapid breathing, confusion, hallucinations, panic, aggressiveness, nausea, vomiting, diarrhea, an irregular heartbeat, and seizures.

See also

sv:Mazindol



Linked-in.jpg